fbpx Yourgene Health plc - Home
004-news.jpg
002-news.jpg
001-news.jpg
003-news.jpg
DSC00185r.jpg
previous arrow
next arrow

Please find below the latest news from Yourgene Health. We also share this news across social media networks.

  • 19 January 2022 - Opening of new Yourgene Health Canada Inc. facilities +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Opening of new Yourgene Health Canada Inc. facilities
    Supporting future growth for Ranger ® Technology

    Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Health Canada Inc. will launch its new expanded facilities at 702 – 1515 Broadway Street, Port Coquitlam, Vancouver, BC V3C 6M2, today from 12:30 (PST).

    The opening will be led by Mayor Brad West, Mayor of Port

    Read More
  • 19 January 2022 - Agreement of new debt facility +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Agreement of new debt facility
    Silicon Valley Bank facility to provide non-dilutive funding for accretive growth opportunities

    Manchester, UK – 19 January 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the Company has entered into a new three-year £5m term loan facility (the “Facility”) with Silicon Valley Bank (“SVB”). The Facility will provide access to non-dilutive funding to enable the Group to capitalise

    Read More
  • 18 January 2022 - US partnership with EKF Diagnostics for NIPT and additional genomic tests +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    US partnership with EKF Diagnostics for NIPT and additional genomic tests
    Collaboration with EKF Diagnostics to use its accredited US laboratories for NIPT and Oncology testing

    Manchester, UK – 18 January 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it has signed a strategic partnership agreement with EKF Diagnostics Holdings plc (“EKF”, AIM: EKF), a point-of-care business with accredited laboratory testing capabilities

    Read More
  • 17 January 2022 - Current year trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Current year trading update
    Further upgrade to full year revenue guidance following strong trading performance

    Manchester, UK – 17 January 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, provides an update on trading for the current financial year ending 31 March 2022.

    The strong trading performance seen in the first half of the year has continued into the second half. Yourgene's high throughput COVID-19 testing

    Read More
  • 23 Dec 21 - DHSC contract awarded to support COVID-19 Winter surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    DHSC contract awarded to support COVID-19 Winter surge testing
    Third contract awarded under PHE National Microbiology Framework Agreement

    Manchester, UK – 23 December 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that Yourgene Genomic Services ('YGS') has been awarded a contract for the provision of laboratory capacity to support the Winter Surge COVID-19 testing by the Department of Health & Social Care (DHSC),

    Read More
  • 14 December 2021 - UKHSA contract award +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    UKHSA contract award
    Contract for the provision of the genetic sequencing services

    Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that Yourgene Genomic Services ('YGS') has been awarded a contract for the provision of genetic sequencing services by the UK Health Security Agency (UKHSA), running until 31 March 2022.

    The contract for the provision of sequencing services is the second contract

    Read More
  • 14 December 2021 - Half-year Report +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    H1 revenues doubled year-on-year
    Full year revenues to exceed already upgraded market expectations

    Manchester, UK – 14 December 2021: Yourgene (AIM: YGEN), a leading integrated technologies and service group enabling the delivery of genomic medicine, announces its unaudited half-year report for the six months ended 30 September 2021 (“H1 FY22”). Unless otherwise stated, comparative data shown is for the six-month period ended 30 September 2020 (“H1

    Read More
  • 18 November 2021 - DPYD screening recommended in Spain +


    Yourgene Health plc
    (“Yourgene” or the “Company”)

    DPYD screening recommended in Spain
    Follows recommendations in Germany, Wales, England and Belgium

    Manchester, UK – 18 November 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, welcomes the publication in Clinical and Translational Oncology, titled: ‘Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fuoropyrimidines

    Read More
  • 28 October 2021 - Yourgene’s Ranger Technology to be presented at Labroots webinar +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene’s Ranger ® Technology to be presented at Labroots webinar

    Manchester, UK – 28 October 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its Ranger® Technology, which was acquired with Coastal Genomics Inc in August 2020, will be presented by Yourgene’s strategic customer, Labcorp, at the Labroots 2021 Clinical Diagnostics and Research Virtual Symposium Event, taking place on Wednesday 10 November 2021.

    During

    Read More
  • 26 October 2021 - Half-year Trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Half-year Trading update
    Improved H1 and year-to-date performance supporting higher full-year expectations

    Manchester, UK – 26 October 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, provides the following update on performance for the six months ended 30 September 2021 (“H1 FY22”), on year-to-date trading and expectations for the full year.

    First half performance (unaudited)

    ● Revenues for the half grew strongly to £17.5m, more than

    Read More
  • 28 September 2021 - AGM Statement Investor presentation +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    AGM Statement
    Investor presentation

    Manchester , UK - 28 September 2021 : Yourgene (AIM: YGEN), a leading international molecular diagnostic group, will be holding its Annual General Meeting (AGM) at 4:00pm today.  In-person registration for this meeting is now closed due to COVID-19 protocols in place but investors can still attend via the Investor Meet Company website as described at the end of this notice.

    At the meeting Adam Reynolds, Non-executive

    Read More
  • 10 September 2021 - Further re: DHSC contract secured to support COVID-19 surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Further re: DHSC contract secured to support COVID-19 surge testing

    Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract Award Notice has been published in relation to its contract with the Department of Health & Social Care (“DHSC”) for the provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing, as announced

    Read More
  • 1 September 2021 - Yourgene Genomic Services receive ISO 15189:2012 accreditation +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services receive ISO 15189:2012 accreditation
    Validating its COVID-19 testing and sequencing services, providing assurance of compliance to international standards to deliver quality levels of performance and competence

    Manchester, UK – 1 September 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following assessments by the UK accreditation service (UKAS), it has received ISO 15189:2012 accreditation for its COVID-19 testing and sequencing services,

    Read More
  • 1 September 2021 - Notice of AGM and Annual Report 2021 +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Notice of AGM and Annual Report 2021
    Investor presentation

    Manchester, UK 1 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that the Notice of Annual General Meeting (“AGM”) and Form of Proxy will shortly be available on the Company’s website at: www.yourgene-health.com/investors/key-documents/shareholder-communications  and are being posted to those shareholders who have opted out of electronic communications.

    The Annual Report and Accounts

    Read More
  • 19 August 2021 - Yourgene’s COVID-19 testing investment reaps rewards DHSC contract secured to support COVID-19 surge testing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene’s COVID-19 testing investment reaps rewards
    DHSC contract secured to support COVID-19 surge testing

    Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, confirms that Yourgene Genomic Services (‘YGS’) has been awarded a contract for provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing by the Department of Health & Social Care (DHSC).

    In April

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen